CD34 and type 2 diabetes mellitus: Based on literature and our past CD34+ve cell based studies, it is likely that circulating CD34+ EPC number, function and mRNA expression can act as a robust cellular biomarker that is more reliable than serum-based biomarkers for monitoring endothelial dysfunction in type 2 diabetes [13–17].